Earnings Summary

CATALYST PHARMACEUTICALS INC’s revenue jumped 98.12% since last year same period to $85.37Mn in the Q1 2023. On a quarterly growth basis, CATALYST PHARMACEUTICALS INC has generated -45.61% fall in its revenue since last 3-months.

CATALYST PHARMACEUTICALS INC’s net profit jumped 123.31% since last year same period to $29.57Mn in the Q1 2023. On a quarterly growth basis, CATALYST PHARMACEUTICALS INC has generated -50.99% fall in its net profits since last 3-months.

CATALYST PHARMACEUTICALS INC’s net profit margin jumped 12.72% since last year same period to 34.64% in the Q1 2023. On a quarterly growth basis, CATALYST PHARMACEUTICALS INC has generated -9.89% fall in its net profit margins since last 3-months.

CATALYST PHARMACEUTICALS INC’s price-to-earnings ratio after this Q1 2023 earnings stands at 13.07.

CATALYST PHARMACEUTICALS INC’s earning per share (EPS) estimates for the current quarter stand at 0.2 - a 5.26% jump from last quarter’s estimates.

CATALYST PHARMACEUTICALS INC’s earning per share (EPS) estimates for the current year stand at 0.2.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. CATALYST PHARMACEUTICALS INC’s return on assets (ROA) stands at 0.23.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. CATALYST PHARMACEUTICALS INC’s return on equity (ROE) stands at 0.36.